Pharmacological therapy targeting the HER2 protein is one of the major breakthroughs in the treatment of cancer patients overexpressing HER2 who have increased survival rates. Despite improved survival, it is important to determine the less frequent adverse effects in order to tailor treatments more personalized to the patients’ features. The possible impact of cancer treatments on cognitive functions is huge, and the effects of anti-HER 2 therapies on this issue have not been reviewed and are the objective of this study. Analysis of PubMed, Scopus, Cochrane library and Web of Science databases revealed six studies performed in breast and serous uterine cancer patients analyzing cognitive function under chemotherapy regimens including anti-HER2 drugs. Four of these studies reported small to significant worsening of cognitive function following chemotherapy regimens containing trastuzumab (the most widely used anti-HER2 drug). In neoadjuvant settings, and in breast cancer patients, treatment with the new anti-HER-2 drug trastuzumab emtansine seems to induce less cognitive impairment than therapeutic regimens containing chemotherapy and trastuzumab. Acute administration of trastuzumab induced cognitive impairment in gastric cancer mice models, confirming its ability to alter cognitive function in patients. More studies analyzing the impact of anti-HER2 therapy on cognitive function are necessary at preclinical and clinical levels in order to personalize pharmacological treatment and offer cancer patients a better quality of life.

针对 HER2 蛋白的药物治疗是治疗过度表达 HER2 并提高生存率的癌症患者的重大突破之一。尽管提高了生存率，但重要的是要确定较少发生的不良反应，以便根据患者的特征定制更个性化的治疗。癌症治疗对认知功能的可能影响是巨大的，抗 HER 2 疗法对这个问题的影响尚未得到审查，这是本研究的目标。对 PubMed、Scopus、Cochrane 图书馆和科学网络数据库的分析显示，在乳腺癌和浆液性子宫癌患者中进行的六项研究分析了化疗方案（包括抗 HER2 药物）下的认知功能。其中四项研究报告称，在接受含有曲妥珠单抗（最广泛使用的抗 HER2 药物）的化疗方案后，认知功能出现小到显着恶化。在新辅助治疗和乳腺癌患者中，与包含化疗和曲妥珠单抗的治疗方案相比，新的抗 HER-2 药物曲妥珠单抗 emtansine 治疗引起的认知障碍似乎更少。曲妥珠单抗的急性给药在胃癌小鼠模型中诱导认知障碍，证实了其改变患者认知功能的能力。有必要在临床前和临床水平进行更多分析抗 HER2 治疗对认知功能影响的研究，以便个性化药物治疗并为癌症患者提供更好的生活质量。与包含化疗和曲妥珠单抗的治疗方案相比，使用新的抗 HER-2 药物曲妥珠单抗 emtansine 进行治疗似乎引起的认知障碍更少。曲妥珠单抗的急性给药在胃癌小鼠模型中诱导认知障碍，证实了其改变患者认知功能的能力。有必要在临床前和临床水平进行更多分析抗 HER2 治疗对认知功能影响的研究，以便个性化药物治疗并为癌症患者提供更好的生活质量。与包含化疗和曲妥珠单抗的治疗方案相比，使用新的抗 HER-2 药物曲妥珠单抗 emtansine 进行治疗似乎引起的认知障碍更少。曲妥珠单抗的急性给药在胃癌小鼠模型中诱导认知障碍，证实了其改变患者认知功能的能力。有必要在临床前和临床水平进行更多分析抗 HER2 治疗对认知功能影响的研究，以便个性化药物治疗并为癌症患者提供更好的生活质量。